Rocky Mountain MS Research Group Statement about Ethics and Disclosures

It is important to us that our patients know and understand our associations and funding sources for outreach programs, physician education programs, and research efforts so that they can make an informed decision regarding potential conflicts of interest.

Consistent with our mission, we strive to make the lives of our patients better through research and education. We provide education to other physicians to aid them in helping their patients and families. Dr. Foley serves on a number of advisory panels and consults primarily regarding the safety aspects of new drug development, as listed below. We also do outreach programs for patients that are sponsored by pharmaceutical companies, enabling us to answer questions from patients and their families on multiple sclerosis related topics.

We also participate in funded and unfunded research designed to answer our own clinical questions that we have and in clinical trials for new drug development. Large, complex research efforts requiring hundreds of hours of staff time and involving many expenses such as laboratory analysis and magnetic resonance imaging may have a budget of several hundred thousand dollars. Many of these activities result in monetary compensation from pharmaceutical companies that allow us to fund various clinic assessments and staff salaries. This compensation also allows us to pursue unfunded research that is not of interest to pharmaceutical companies, but that may help us to answer questions about MS. We appreciate the potential conflict of interest and rigorously review all our programs for consistency with our mission. We invite you to discuss any of these issues with us at any time.

DISCLOSURES FOR › JOHN F. FOLEY, MD

Dr. Foley currently sits on several scientific advisory boards, including: Biogen Idec and Elan since 2008; Genzyme/Sanofi-Aventis since April 2011; and Avanir since May 2011.

Dr. Foley is a current participant in the Speakers’ Bureaus for both Biogen Idec and Teva and has been since 1995.

Dr. Foley is a current participant in the Speakers’ Bureau for Questcor as of July 2011.

Dr. Foley is a consultant for Genentech and has been since 2009.

Dr. Foley does not receive stock, stock options, or royalties from any of these entities. Honoraria received is remitted to Rocky Mountain Multiple Sclerosis Clinic or Rocky Mountain MS Research Group.

DISCLOSURES FOR › VITA KAPLAN, MD

Dr. Kaplan is a current participant in the Speaker’s Bureau for Biogen Idec and has been since 2010; she has also been so for Teva and Questcor since 2011.

DISCLOSURES FOR › ROBERT M. MISKA, MD

Dr. Miska does not have any conflicts of interest or disclosures at this time. 

DISCLOSURES FOR › LIQUN ZHOU, MD

Dr. Zhou does not have any conflicts of interest or disclosures at this time. 

DISCLOSURES FOR › CORTNEE L. ROMÁN, MSN, FNP-C, MSCN

Cortnee is a consultant for Acorda Therapeutics, Biogen & Elan Pharmaceuticals, Teva Neuroscience, Pfizer, EMD Serono, and the National Multiple Scerlosis Society Utah-Southern Idaho Chapter.